Compare drug alternatives
Invokamet® Alternatives
Invokamet®(canagliflozin / metformin) | Steglujan®(ertugliflozin / sitagliptin) |
---|---|
Prescription Only | Prescription Only |
Dosage & Administration | |
Administration | |
Oral . Learn more. | Oral . Learn more. |
Dosing | |
INVOKAMET XR: two tablets, once daily with the morning meal. Swallow whole. Never crush, cut, or chew. . Learn more. | Recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily, taken in the morning, with or without food. Increase dose to 15 mg ertugliflozin/100 mg sitagliptin once daily in those tolerating STEGLUJAN for additional glycemic control. . Learn more. |
Latin Shorthand | |
2 tabs, 1x daily with AM meal. Swallow whole, do not crush, cut, or chew.. Learn more. | 5 mg ertugliflozin/100 mg sitagliptin qd in AM, with or without food. Increase to 15 mg ertugliflozin/100 mg sitagliptin qd for those tolerating STEGLUJAN and needing additional glycemic control.. Learn more. |
Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $0. Learn more. |
Annual Cap | |
$3000 and $200 per month. Learn more. | $583 per fill . Learn more. |
Assistance Expiration | |
Calendar year. Learn more. | 12 uses. Learn more. |
Generics | |
No lower-cost generic available | No lower-cost generic available |
Physician Advisory | |
Adverse Reactions | |
Most common adverse reactions associated with canagliflozin (5% or
greater incidence): female genital mycotic infections, urinary tract
infection, and increased urination.
Most common adverse reactions associated with metformin HCl (5% or
greater incidence) are diarrhea, nausea, vomiting, flatulence, asthenia,
indigestion, abdominal discomfort, and headache.. Learn more. | Most common adverse reactions associated with ertugliflozin
(incidence ≥5%): female genital mycotic infections.
Most common adverse reactions associated with sitagliptin
(incidence ≥5%): upper respiratory tract infection, nasopharyngitis
and headache. In the add-on to sulfonylurea and add-on to insulin
studies, hypoglycemia was also more commonly reported in patients
treated with sitagliptin compared to placebo.. Learn more. |
Mechanism of Actions (MoA) | |
SGLT2 Inhibitors. Learn more. | SGLT2 Inhibitors. Learn more. |
Special Populations | |
Popular Alternatives
- Invokamet® vs Victoza
- Invokamet® vs Trulicity
- Invokamet® vs Skyclarys
- Invokamet® vs Skyclarys
- Invokamet® vs Ozempic
- Invokamet® vs Rybelsus
- Invokamet® vs Mounjaro
- Invokamet® vs Bydureon®
- Invokamet® vs Invokamet
- Invokamet® vs Invokana
- Invokamet® vs Farxiga
- Invokamet® vs Glyxambi
- Invokamet® vs Jardiance
- Invokamet® vs Synjardy
- Invokamet® vs Trijardy XR®
- Invokamet® vs Segluromet
- Invokamet® vs Steglatro
- Invokamet® vs Inpefa